These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization. Yildirim H; Aydemir O; Balbaba M; Özercan İH; İlhan N Cutan Ocul Toxicol; 2020 Sep; 39(3):223-228. PubMed ID: 32338080 [TBL] [Abstract][Full Text] [Related]
6. The role of microRNAs in corneal neovascularization and its relation to VEGF. Yaşar M; Çakmak H; Dündar S; Örenay Boyacıoğlu S; Çalışkan M; Ergin K Cutan Ocul Toxicol; 2020 Dec; 39(4):341-347. PubMed ID: 32854552 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model. Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization. Keskin U; Totan Y; Karadağ R; Erdurmuş M; Aydın B Ophthalmic Res; 2012; 47(1):13-8. PubMed ID: 21691137 [TBL] [Abstract][Full Text] [Related]
10. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169 [TBL] [Abstract][Full Text] [Related]
12. Effect of topical motesanib in experimental corneal neovascularization model. Çelenk M; Yıldırım H; Tektemur A; Balbaba M; Erdağ M Int Ophthalmol; 2023 Aug; 43(8):2989-2997. PubMed ID: 36971928 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Manzano RP; Peyman GA; Khan P; Carvounis PE; Kivilcim M; Ren M; Lake JC; Chévez-Barrios P Br J Ophthalmol; 2007 Jun; 91(6):804-7. PubMed ID: 17179168 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the Effects of Subconjunctival Injections of Bevacizumab and Interferon Alpha-2a on Corneal Angiogenesis in a Rat Model. Bilgin S Medicina (Kaunas); 2018 Apr; 54(2):. PubMed ID: 30344247 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774 [TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits. Kadar T; Amir A; Cohen L; Cohen M; Sahar R; Gutman H; Horwitz V; Dachir S Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293 [TBL] [Abstract][Full Text] [Related]
17. Antiangiogenesis Effect of Albendazole on the Cornea. Cho YK; Shin EY; Uehara H; Ambati B J Ocul Pharmacol Ther; 2019 May; 35(4):254-261. PubMed ID: 31033390 [No Abstract] [Full Text] [Related]
18. Anti-angiogenic effect of KR-31831 on corneal and choroidal neovascularization in rat models. Kim IT; Park HY; Choi JS; Joo CK Invest Ophthalmol Vis Sci; 2012 May; 53(6):3111-9. PubMed ID: 22491414 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Sunitinib, Sunitinib-Hesperetin, and Sunitinib-Doxycycline Combinations on Experimentally-Induced Corneal Neovascularization. Ekim Y; Kara S; Gencer B; Karaca T Curr Eye Res; 2019 Jun; 44(6):590-598. PubMed ID: 30803276 [No Abstract] [Full Text] [Related]
20. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model. Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]